📖 Essentials of Medical Pharmacology (8th Ed.) - KD Tripathi

Structure (14 Sections, 71 Chapters):

Content Confirmed:

• Routes of drug administration and dosage forms
• Pharmacokinetics - absorption, distribution, metabolism, excretion
• Pharmacodynamics - receptor pharmacology, dose-response relationships
• Drug interactions, synergism, antagonism
• Adverse drug effects - toxicity, allergy, teratogenicity
• Clinical pharmacology and drug development (Phase I-IV trials)
• Rational use of medicines

Drug-Receptor Interaction

Based on KD Tripathi's Essentials of Medical Pharmacology, 8th Edition (Chapter 4)

1. What is a Receptor?

"A receptor is a macromolecule or binding site located on the surface or inside the effector cell that serves to recognize the signal molecule/drug and initiate the response to it, but itself has no other function."

• Receptors are regulatory macromolecules, mostly proteins
• They have two essential domains:
  • Ligand binding domain - recognizes and binds the specific drug/signal molecule
  • Effector domain - undergoes conformational change to produce the response

2. Key Terminology

3. Receptor Occupation Theory (Clark, 1937)

• Affinity - ability to bind to the receptor. Higher affinity = effective at lower concentrations
• Intrinsic Activity (IA) / Efficacy - ability to activate (induce conformational change in) the receptor once bound

Example: Buprenorphine has 25× higher affinity than morphine for the µ-opioid receptor, yet it is only a partial agonist - its lower ceiling response is NOT due to lower affinity, but lower intrinsic activity.

4. The Two-State Receptor Model

• Ra (active state) → generates signal
• Ri (inactive state) → no signal

Inverse agonism is only manifest when the receptor has constitutive activation (e.g., benzodiazepine receptor). DMCM is an inverse agonist at the benzodiazepine receptor.

5. Five Major Receptor Families & Transducer Mechanisms

A. G-Protein Coupled Receptors (GPCRs)

• Structure: 7 transmembrane helical segments
• Mechanism: Agonist → receptor → activates G-protein (α subunit binds GTP, dissociates) → activates effector
• Three major pathways:
  1. Adenylyl cyclase/cAMP pathway (Gs activates, Gi inhibits AC → PKA → phosphorylates proteins)
  2. Phospholipase C / IP₃-DAG pathway (Gq → PLCβ → IP₃ + DAG → Ca²⁺ release + PKC activation)
  3. Channel regulation (Gs opens Ca²⁺ channels; Gi/Go open K⁺ channels)
• Onset: Seconds
• Examples: β-adrenergic, muscarinic, histamine, opioid receptors

B. Ion Channel Receptors (Ligand-Gated Ion Channels)

• Structure: Pentameric protein enclosing an ion channel
• Mechanism: Agonist binding directly opens channel → ion flow → depolarization/hyperpolarization
• Onset: Fastest — milliseconds
• Examples: Nicotinic cholinergic (Na⁺), GABA-A (Cl⁻), Glutamate-NMDA, 5-HT₃

C. Transmembrane Enzyme-Linked Receptors (Receptor Tyrosine Kinases - RTKs)

• Mechanism: Hormone binding → receptor dimerization → tyrosine kinase activation → autophosphorylation → cascade of phosphorylations
• Onset: Minutes to hours
• Examples: Insulin receptor, EGF receptor, NGF receptor

D. Transmembrane JAK-STAT Receptors

• Mechanism: Agonist → dimerization → binds JAK → JAK phosphorylates receptor → STAT binds → STAT dimerizes → moves to nucleus → gene transcription
• Examples: Cytokines, Growth hormone, Prolactin, Interferons

E. Nuclear Receptors (Transcription Factors)

• Location: Intracellular (cytoplasmic or nuclear)
• Mechanism: Lipid-soluble ligand penetrates cell → binds receptor (releases HSP-90) → receptor dimerizes → moves to nucleus → binds hormone response elements on DNA → alters gene expression → new protein synthesis
• Onset: Slowest — hours; effects outlast the signal
• Examples: Glucocorticoids, mineralocorticoids, androgens, estrogens, thyroxine, Vit D, Vit A

6. Spare Receptors

• Many full agonists produce maximal response while occupying <1% of available receptors
• A large receptor reserve (spare receptors) exists
• For some drugs, total receptor number limits the maximal response - no spare receptors

7. Regulation of Receptors

Down-regulation (Desensitization/Refractoriness)

• Masking or internalization of receptor (fast, reversible) - e.g., β-adrenergic receptor phosphorylation by βARK → β-arrestin binding → impaired coupling to Gs
• Decreased synthesis / increased destruction (slow, weeks to months) - especially seen with RTKs

Up-regulation (Supersensitivity)

• Receptor proliferation
• Accentuation of signal amplification
• Clinical examples: Clonidine/opioid/propranolol withdrawal syndromes

Types of Desensitization:

• Homologous - only agonists of the same receptor are affected (βARK-arrestin mechanism)
• Heterologous - agonists acting through different receptors also desensitize (PKA/PKC mechanism)

8. Drug Antagonism at Receptors

Competitive (Equilibrium) Antagonism

• Antagonist binds same site as agonist, is chemically similar
• Binding is reversible → higher agonist concentration can overcome block
• Result: Parallel rightward shift of agonist DRC, no suppression of maximal response (surmountable)
• Examples: ACh–Atropine; Morphine–Naloxone

Noncompetitive Antagonism

• Antagonist binds different (allosteric) site
• Agonist cannot compete → even high agonist concentration cannot fully reverse block
• Result: Flattening of agonist DRC, maximal response suppressed (unsurmountable)
• Not in clinical use

Nonequilibrium Antagonism

• Antagonist binds with covalent bonds or very high affinity → irreversible
• Agonist DRC shifts rightward AND maximal response is lowered
• Example: Phenoxybenzamine (non-equilibrium antagonist at α-adrenergic receptors)

9. Summary Table: Agonist vs Antagonist Properties

Drug-Receptor Interaction: The Binding Concept

1. The Basic Interaction

• This interaction obeys the Law of Mass Action
• The binding is mostly reversible and non-covalent
• Forces involved: ionic bonds, hydrogen bonds, van der Waals forces

2. Two Key Properties

Affinity

• The tendency/strength of the drug to bind to the receptor
• Measured by KD (dissociation constant)
• Lower KD = Higher affinity (drug binds at lower concentration)
• Affinity tells you how much drug is needed, not what it does

Intrinsic Activity (Efficacy)

• The ability of the drug to activate the receptor after binding
• Ranges from 0 to 1
• Affinity and intrinsic activity are completely independent of each other

A drug can have high affinity but zero intrinsic activity - that's a competitive antagonist. A drug can have high affinity but only partial intrinsic activity - that's a partial agonist.

3. The Binding Equation & Curve

• E = effect observed at dose [D]
• Emax = maximum possible response
• KD = dose at which 50% of receptors are occupied (= 50% effect)

The Binding Curve:

Effect
  |
Emax|- - - - - - - - - - - -
  |                ________
  |           ____/
50%|__________/
  |      /
  |_____/____________________
              KD        Dose

• At low doses → small effect, curve rises steeply
• As dose increases → effect increase slows down (receptors getting saturated)
• Shape is a rectangular hyperbola
• When plotted as log dose vs effect → becomes a sigmoid (S-shaped) curve
• The linear portion of the sigmoid curve (30-70% response range) is the most clinically useful range

4. What KD Tells You

5. Occupancy vs Response

• Effect is directly proportional to the number of receptors occupied by the drug
• BUT - 100% receptor occupancy is NOT needed for maximal effect
• Many drugs produce Emax by occupying only a fraction of receptors
• The remaining unoccupied ones are called Spare Receptors

In Short - What to Write in an Introduction:

Drug Binding to Receptors & The Binding Curve

5-Mark Answer (Based on your page - Chapter 2, Pharmacology)

1. Distinction Between Drug Binding and Receptor Activation (Fig. 2.2)

For an Agonist (Drug A):

Drug A + R  ⇌  AR  ⇌  AR*  →  Response
         K+1      β
         K-1      α

• Occupation (Drug A + R → AR) is governed by Affinity
• Activation (AR → AR*) is governed by Efficacy
• So binding and activation are TWO SEPARATE STEPS

For an Antagonist (Drug B):

Drug B + R  ⇌  BR  →  NO Response
         K+1
         K-1

• Antagonist occupies the receptor (has affinity)
• But cannot activate it (zero efficacy)
• So it produces No Response

Key Point: Occupation ≠ Activation. A drug must BOTH bind AND activate to produce a response.

2. How Drug Binding is Measured

• Drug molecules (agonists or antagonists) are labelled with radioactive atoms - usually ³H, ¹⁴C, or ¹²⁵I
• Tissue samples (or membrane fragments) are incubated with various concentrations of the radioactive drug
• Incubation continues until equilibrium is reached - meaning:
  • Rate of association (binding) = Rate of dissociation (unbinding)
• After equilibrium, bound radioactivity is measured after removal of the supernatant
• This gives a direct measure of how much drug has bound to receptors

3. The Binding Curve (Fig. 2.3)

Graph A - Linear Scale (Rectangular Hyperbola):

• X-axis: Concentration (nmol/L) - linear scale (0, 5, 10, 15, 20)
• Y-axis: Specifically bound drug (fmol/mg)
• Shape: Rectangular hyperbola
• Curve rises steeply at low concentrations then flattens out toward Bmax

Graph B - Log Scale (Sigmoid Curve):

• X-axis: Concentration (nmol/L) - logarithmic scale (0.001, 0.01, 0.1, 1, 10, 100)
• Y-axis: Specifically bound drug (fmol/mg)
• Shape: Symmetrical sigmoid (S-shaped) curve
• K is marked on the graph = concentration at 50% receptor occupancy

4. Two Things the Binding Curve Tells You

A. Bmax (Binding Capacity / Maximum Binding)

• The plateau of the curve
• Represents the total density of receptors in that tissue
• When all receptors are occupied → no further increase in binding even if drug concentration increases
• Unit: fmol/mg of tissue

B. Equilibrium Dissociation Constant (K)

• Marked on Graph B
• Numerically equal to the concentration of drug required to occupy 50% of the receptor sites at equilibrium
• It is a measure of affinity:
  • Lower K = Higher affinity (drug occupies 50% receptors at very low concentration)
  • Higher K = Lower affinity (needs more drug to occupy 50% receptors)
• Has dimensions of concentration (nmol/L)

5. Spare Receptor Hypothesis

• When binding studies are combined with functional studies, an important finding emerged:
• Agonists bind with rather low affinity to muscarinic receptors in smooth muscle
• Yet a maximal biological effect occurs at low receptor occupancy
• This confirms the Spare Receptor Hypothesis - you do NOT need to occupy all receptors to get maximum response
• Extra unoccupied receptors = Spare receptors

5-Mark Answer (Write This in Exam):

1. Occupation - governed by affinity
2. Activation - governed by efficacy An agonist occupies AND activates (→ Response). An antagonist only occupies, not activates (→ No Response).

• On linear scale → rectangular hyperbola
• On log scale → symmetrical sigmoid curve

• Bmax - maximum binding = represents receptor density in tissue
• K (equilibrium dissociation constant) - concentration at 50% occupancy = measure of affinity. Lower K = higher affinity.

Drug Binding to Receptors - The Story

The Story Begins - Two Steps, Not One

• Drug A (Agonist) - fits the lock AND turns it → Door opens → Response
• Drug B (Antagonist) - fits the lock perfectly BUT cannot turn it → Door stays shut → No Response

Now Scientists Wanted to MEASURE This Binding

The Binding Curve - Reading the Story in the Graph

What is K and Why Does it Matter?

The Surprising Ending - Spare Receptors

The Complete Story in One Flow:

1. Pure paragraph style - just flowing written paragraphs like an essay
2. Headings + paragraphs - small headings with explanation under each
3. Points format - numbered or bulleted points
4. Mixed - short intro paragraph, then points, then conclusion

Drug Binding to Receptors

5-Mark Exam Answer

Binding vs Activation (Fig. 2.2)

• Occupation of the receptor is governed by Affinity - the strength with which the drug holds onto the receptor
• Activation of the receptor is governed by Efficacy - the ability of the drug to produce a conformational change after binding

• An agonist (Drug A) - binds AND activates → produces a response
• An antagonist (Drug B) - binds but does NOT activate → produces no response

Measurement of Drug Binding

The Binding Curve (Fig. 2.3)

• Graph A (Linear scale) - gives a rectangular hyperbola. The curve rises steeply at low concentrations as receptors get occupied, then gradually flattens as receptors become saturated, finally reaching a plateau.
• Graph B (Log scale) - the same data plotted on a logarithmic concentration scale gives a symmetrical sigmoid (S-shaped) curve, which is more useful for reading values accurately.

Two Key Parameters From the Curve

• The plateau of the curve
• Represents the maximum number of receptors available in the tissue
• Reflects receptor density

• The concentration of drug at which 50% of receptors are occupied
• Marked clearly on Graph B
• Directly reflects affinity of the drug for the receptor
• Lower K = Higher affinity (drug binds tightly at low concentration)
• Higher K = Lower affinity (more drug needed to occupy half the receptors)

Spare Receptor Hypothesis

Summary

1. MBBS 1st year - need basic understanding of all 5 types of receptors
2. MBBS 2nd year or above - need deeper detail on each pathway
3. Pharmacy / Nursing - need moderate detail